A Phase 2 interventional study of APL-9796 and APL-9796 in Pulmonary Arterial Hypertension, sponsored by Apollo Therapeutics Ltd. Recruiting at 6 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Apollo Therapeutics Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom — 11 open to participants now, 18 under way, 6 of them phase 3. Pulmonary Arterial Hypertension · United Kingdom.
Among the 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom, this one is the 65th largest by planned enrollment of the 91 interventional ones that give a count, is one of 2 that started in 2025, is one of 25 in phase 2, reaches primary completion later than 7 of the 17 other live ones, and was the 90th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →11 of the 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:
35Pharma Inc., a GSK company · Sites in United Kingdom, United States, Spain
Ages 18+
University of Glasgow · Sites in United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 18+
Inhibikase Therapeutics · Sites in United Kingdom, United States, Argentina and 11 more countries
Ages 18–75
Golden Jubilee National Hospital · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 33 · Phase 3 40 · Phase 4 9
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 108 across the 91 interventional studies, 65 across the 7 observational. Of the 76 that completed or were terminated, 49 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 98 have an industry lead sponsor. The 10 most frequent:
Apollo Therapeutics Ltd is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Apollo Therapeutics Ltd has 1 study filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Arterial Hypertension with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT07366879Golden Jubilee National HospitalExercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension | 2027-08 |
| NCT06846554Apollo Therapeutics LtdA Trial of "APL-9796'' in Adults With Pulmonary Hypertension | 2027-08-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796.
The trial will be conducted in two parts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three (3) APL-9796 dose levels are planned for evaluation using BOIN design.
Drug: APL-9796
Cohorts will be enrolled sequentially at N=4, at a dose level determined by the Safety Review Committee (SRC) based on data from Part A.
Drug: APL-9796
3 Cohorts are planned in Part A.
The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Number of participants who experience Treatment-Emergent Adverse Events will be reported which also include the frequency, severity (CTCAE V5.0) and relationship (causality) of AEs
Time frame: Through study completion (approximately 2 years)
To assess the Telemetry Parameters
Telemetry parameter is assessed using Total pulmonary resistance (TPR)
Time frame: from baseline (CFB) to Day 169
To assess the Telemetry Parameters
Telemetry parameter is assessed using Pulmonary arterial pressures: systolic, diastolic and mean (mPAP)
Time frame: from baseline (CFB) to Day 169
To assess Six minute walk test / Six minute walk distance (6MWD)
A 6-minute walk test (6MWT) is assessed per the guidelines of the American Thoracic Society 2003
Time frame: from baseline (CFB) to Day 169
To assess NT-proB-type Natriuretic Peptide (NT-proBNP)
The level of NT-proBNP is assessed by blood sample collection and analysis
Time frame: from baseline (CFB) to Day 169
To assess the Quality of life
Quality of life is assessed using SF-36 questionnaire
Time frame: from baseline (CFB) to Day 169
To assess the Quality of life
Quality of life is assessed using emPHasis-10 questionnaire
Time frame: from baseline (CFB) to Day 169
To evaluate the PK of APL-9796 in participants with PH
APL-9796 concentrations in serum
Time frame: at each visit (approximately every 28 days until day 169), then day 254, day 339 and day 508
To evaluate the immunogenicity of APL-9796 in participants with PH.
* Incidence of anti-drug antibody (ADA) against APL-9796 (including titres) * Incidence of neutralising antibody (Nab) against APL-9796 (including titres)
Time frame: at each visit (approximately every 28 days until day 169), then day 254, day 339 and day 508
Started Apr 2025 (actual). Primary completion is estimated for Aug 2027, 28 months after the start.
Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 28 months is close to that.
Counting every sponsor, half of 52 studies reached it within 44 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
Apollo Therapeutics Ltd